Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have updated their coverage on the stock in […]
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) – Equities researchers at Lifesci Capital increased their FY2023 earnings estimates for Olema Pharmaceuticals in a note issued to investors on Monday, October 23rd. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings per share of ($2.46) for the year, up from their prior […]
Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was.